Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Lindberg S, Pedersen SH, Mogelvang R, Galatius S, Flyvbjerg A, Jensen JS, Bjerre M.

Am Heart J. 2012 Nov;164(5):786-92. doi: 10.1016/j.ahj.2012.08.018. Epub 2012 Oct 17.

PMID:
23137511
2.

Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Lindberg S, Pedersen SH, Mogelvang R, Jensen JS, Flyvbjerg A, Galatius S, Magnusson NE.

J Am Coll Cardiol. 2012 Jul 24;60(4):339-45. doi: 10.1016/j.jacc.2012.04.017.

3.

Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Lindberg S, Pedersen SH, Møgelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Jensen JS.

Am J Cardiol. 2012 Feb 15;109(4):492-6. doi: 10.1016/j.amjcard.2011.09.041. Epub 2011 Nov 19.

PMID:
22105783
4.

High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention.

Bjerre M, Pedersen SH, Møgelvang R, Lindberg S, Jensen JS, Galatius S, Flyvbjerg A.

Eur J Prev Cardiol. 2013 Dec;20(6):922-9. doi: 10.1177/2047487313487083. Epub 2013 Apr 23.

PMID:
23613225
5.

Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.

Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR.

Am J Cardiol. 2012 Dec 15;110(12):1756-63. doi: 10.1016/j.amjcard.2012.08.008. Epub 2012 Sep 13.

PMID:
22981263
6.

MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI.

Lindberg S, Jensen JS, Pedersen SH, Galatius S, Goetze JP, Mogelvang R.

Eur J Prev Cardiol. 2015 Jun;22(6):693-700. doi: 10.1177/2047487314538856. Epub 2014 Jun 6.

PMID:
24906365
7.

Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction-a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy.

Maeng M, Nielsen PH, Busk M, Mortensen LS, Kristensen SD, Nielsen TT, Andersen HR; DANAMI-2 Investigators.

Am J Cardiol. 2010 Jun 1;105(11):1528-34. doi: 10.1016/j.amjcard.2010.01.005. Epub 2010 Apr 14.

PMID:
20494656
8.

Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Sørensen TB, Iversen A, Hvelplund A, Jensen JS.

Cardiology. 2012;123(1):31-8. doi: 10.1159/000339880. Epub 2012 Sep 7.

9.

Level of complement activity predicts cardiac dysfunction after acute myocardial infarction treated with primary percutaneous coronary intervention.

Haahr-Pedersen S, Bjerre M, Flyvbjerg A, Mogelvang R, Dominquez H, Hansen TK, Galatius S, Bech J, Madsen JK, Søgaard P, Jensen JS.

J Invasive Cardiol. 2009 Jan;21(1):13-9.

10.

Plasma B-type natriuretic peptide level can predict myocardial tissue perfusion in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.

Seo SM, Kim S, Chang K, Min J, Kim TH, Koh YS, Park HJ, Shin WS, Lee JM, Kim PJ, Chung WS, Seung KB.

Coron Artery Dis. 2011;22(6):405-10. doi: 10.1097/MCA.0b013e3283487dac.

PMID:
21701385
11.

Quartiles of peak troponin are associated with long-term risk of death in type 1 and STEMI, but not in type 2 or NSTEMI patients.

Gonzalez MA, Porterfield CP, Eilen DJ, Marzouq RA, Patel HR, Patel AA, Nasir S, Lim HM, Babb JD, Rose JD, Cascio WE; Multidisciplinary Atherothrombosis Prevention Program (MAPP).

Clin Cardiol. 2009 Oct;32(10):575-83. doi: 10.1002/clc.20662.

12.

Interplay Between Adiponectin and Pro-Atrial Natriuretic Peptide and Prognosis in Patients With ST-Segment Elevation Myocardial Infarction.

Lindberg S, Jensen JS, Hoffmann S, Pedersen SH, Iversen AZ, Galatius S, Frystyk J, Flyvbjerg A, Goetze JP, Bjerre M, Mogelvang R.

Am J Cardiol. 2015 Nov 1;116(9):1340-5. doi: 10.1016/j.amjcard.2015.07.060. Epub 2015 Aug 15.

PMID:
26361828
13.

Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction.

Huang SS, Huang PH, Chen YH, Sung SH, Chiang KH, Chen JW, Lin SJ.

Coron Artery Dis. 2008 Dec;19(8):597-602. doi: 10.1097/MCA.0b013e3283155579.

PMID:
18971786
14.

Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging.

Fuernau G, Zaehringer S, Eitel I, de Waha S, Droppa M, Desch S, Schuler G, Adams V, Thiele H.

Int J Cardiol. 2013 Sep 1;167(5):2134-9. doi: 10.1016/j.ijcard.2012.05.101. Epub 2012 Jun 15.

PMID:
22704876
15.

Comparison of infarct-related artery vs multivessel revascularization in ST-segment elevation myocardial infarction with multivessel disease: analysis from Korea Acute Myocardial Infarction Registry.

Lee HW, Hong TJ, Yang MJ, An SG, Oh JH, Choi JH, Lee HC, Cha KS, Hong JY; Korea Acute Myocardial Infarction Registry Investigators.

Cardiol J. 2012;19(3):256-66.

16.
18.

The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction.

Erkol A, Oduncu V, Turan B, Kılıçgedik A, Sırma D, Gözübüyük G, Karabay CY, Guler A, Dündar C, Tigen K, Pala S, Kırma C.

J Thromb Thrombolysis. 2014 Oct;38(3):339-47. doi: 10.1007/s11239-013-1044-3.

PMID:
24407374
19.

Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Brkovic V, Dobric M, Beleslin B, Giga V, Vukcevic V, Stojkovic S, Stankovic G, Nedeljkovic MA, Orlic D, Tomasevic M, Stepanovic J, Ostojic M.

Int J Cardiovasc Imaging. 2013 Aug;29(6):1215-28. doi: 10.1007/s10554-013-0202-1. Epub 2013 Feb 27.

PMID:
23443340
20.

Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.

Stankovic S, Asanin M, Trifunovic D, Majkic-Singh N, Miljković A, Ignjatovic S, Mrdovic I, Matic D, Savic L, Ostojic M, Vasiljevic Z.

Clin Lab. 2012;58(11-12):1135-44.

PMID:
23289182
Items per page

Supplemental Content

Write to the Help Desk